Breaking News
Sort by:
Top Post
Experimental Cancer Drug May Slow Inflammation Linked to Heart Disease
An experimental drug already tested as a potential treatment for cancer, lung, and Alzheimer’s disease […]
CardiaCare Names Ken Nelson Chairman of its Board of Directors
CardiaCare, a clinical-stage digital therapeutic company developing the world’s first non-invasive, neuromodulation wearable for atrial […]
Temple Therapeutics Reveals Breakthrough Findings on Ovarian Cancer at AACR 2023
Temple Therapeutics, a biotechnology company pioneering a female-focused precision medicine approach, presented new in vitro […]
Gene & Cell Therapy Manufacturing Specialist Ascend Launches With Over $130M of Funding
Ascend Gene & Cell Therapies (Ascend), a specialist company innovating manufacturing processes to improve quality, […]
Anona Bamford Ph.D., PerkinElmer Applied Genomics, on Single-Cell RNA Sequencing
In this interview with Anona Bamford from PerkinElmer at the 33rd ECCMID 2023 event, she […]
SynCrest Launches CRDMO Service for Peptide-based Therapeutics
SynCrest, a peptide and nucleotide CRDMO (Contract Research, Development and Manufacturing Organization) joint venture between […]
Life Biosciences and Forge Biologics Announce cGMP Manufacturing Partnership to Advance Development of Novel Gene Therapies for Aging-Related Diseases
Life Biosciences (“Life Bio”), a biotechnology company advancing innovative cellular rejuvenation technologies to reverse diseases […]
Solarea Bio Announces First Close of Series B Financing Round
Solarea Bio, a clinical-stage biotechnology company based in Cambridge, MA developing food-derived microbial-based solutions to […]
MTA's ECCMID 2023 Highlight Reel
The 33rd ECCMID (European Congress of Clinical Microbiology and Infectious Diseases) is a scientific conference […]
Neuro3 Therapeutics Acquires Exclusive Worldwide Rights to Develop and Commercialize Clinical Stage KCNQ2 Activators from Lundbeck
Neuro3 Therapeutics (Neuro3), a biotechnology company focused on the discovery and development of innovative medicines […]
Telix to Supply Bayer with Illuccix® for Global Phase III Prostate Cancer Study
Telix Pharmaceuticals today announces that it has entered into an agreement with Bayer AG (Bayer) […]
- Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
- Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
- DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
- Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
- Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more